CA2397813A1 - Methode et reactif d'inhibition de grid - Google Patents
Methode et reactif d'inhibition de grid Download PDFInfo
- Publication number
- CA2397813A1 CA2397813A1 CA002397813A CA2397813A CA2397813A1 CA 2397813 A1 CA2397813 A1 CA 2397813A1 CA 002397813 A CA002397813 A CA 002397813A CA 2397813 A CA2397813 A CA 2397813A CA 2397813 A1 CA2397813 A1 CA 2397813A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid molecule
- rna
- grid
- enzymatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La présente invention concerne des molécules d'acides nucléiques, notamment des molécules d'acides nucléiques anti-sens et enzymatiques, telles que des ribozymes à tête de marteau, des désoxyribozymes (ADNzymes), et anti-sens, lesquelles modulent l'expression du gène GRID (apparenté Grb2 avec domaine d'insertion).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18459400P | 2000-02-24 | 2000-02-24 | |
US60/184,594 | 2000-02-24 | ||
PCT/US2001/005957 WO2001062911A2 (fr) | 2000-02-24 | 2001-02-23 | Methode et reactif d'inhibition de grid |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2397813A1 true CA2397813A1 (fr) | 2001-08-30 |
Family
ID=22677548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002397813A Abandoned CA2397813A1 (fr) | 2000-02-24 | 2001-02-23 | Methode et reactif d'inhibition de grid |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3986201A (fr) |
CA (1) | CA2397813A1 (fr) |
WO (1) | WO2001062911A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006064519A2 (fr) * | 2004-12-14 | 2006-06-22 | National Institute Of Immunology | Adnzymes destinees a l'inhibition de la replication du virus de l'encephalite japonaise |
CN109971836A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 双重荧光定量pcr测定car拷贝数的方法和试剂盒 |
CN109971837A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种外源抗体基因拷贝数的检测方法和试剂盒 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5861288A (en) * | 1993-10-18 | 1999-01-19 | Ribozyme Pharmaceuticals, Inc. | Catalytic DNA |
US6103890A (en) * | 1994-05-18 | 2000-08-15 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids that cleave C-fos |
CA2253382A1 (fr) * | 1996-01-16 | 1997-07-24 | Ribozyme Pharmaceuticals, Inc. | Synthese de methoxy nucleosides et de molecules d'acide nucleique enzymatique |
US7309692B1 (en) * | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
US5874224A (en) * | 1997-03-11 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Growth factor receptor binding protein |
JP2002512794A (ja) * | 1998-04-29 | 2002-05-08 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | ヌクレオチド三リン酸およびリボザイム内へのそれらの取り込み |
GB9818124D0 (en) * | 1998-08-19 | 1998-10-14 | Glaxo Group Ltd | CD28 binding protein |
-
2001
- 2001-02-23 CA CA002397813A patent/CA2397813A1/fr not_active Abandoned
- 2001-02-23 WO PCT/US2001/005957 patent/WO2001062911A2/fr active Search and Examination
- 2001-02-23 AU AU39862/01A patent/AU3986201A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001062911A3 (fr) | 2002-02-07 |
AU3986201A (en) | 2001-09-03 |
WO2001062911A2 (fr) | 2001-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6831171B2 (en) | Nucleic acid catalysts with endonuclease activity | |
US20030064945A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
US20030191077A1 (en) | Method and reagent for the treatment of asthma and allergic conditions | |
AU748176B2 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
US20030124513A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV | |
US20030216335A1 (en) | Method and reagent for the modulation of female reproductive diseases and conditions | |
US20040142895A1 (en) | Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway | |
US20030203870A1 (en) | Method and reagent for the inhibition of NOGO and NOGO receptor genes | |
WO2001057206A2 (fr) | Procede et reactif destines a inhiber la checkpoint kinase-1 (chk 1) | |
WO2001088124A2 (fr) | Procede et reactif destine a l'inhibition d'erg | |
US20020102694A1 (en) | Nucleozymes with endonuclease activity | |
EP1257639A2 (fr) | Nucleozymes a activite d'endonuclease | |
WO2003102131A2 (fr) | Dissociation assistee par des acides nucleiques des interactions de peptides fusogeniques | |
US20040102389A1 (en) | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) | |
EP1165758A2 (fr) | Regulation de genes represseur avec des molecules d'acide nucleique | |
CA2397813A1 (fr) | Methode et reactif d'inhibition de grid | |
US20030087847A1 (en) | Method and reagent for the inhibition of checkpoint kinase-1 (Chk1) enzyme | |
US20030073207A1 (en) | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
WO1999050403A2 (fr) | Procede et reactifs pour le traitement de maladies ou d'affections associees a des molecules impliquees dans les reactions angiogeniques | |
US20030050259A1 (en) | Method and reagent for the treatment of cardiac disease | |
US20030064946A1 (en) | Method and reagent for the inhibition of calcium activated chloride channel-1 (CLCA-1) | |
US20030113891A1 (en) | Method and reagent for the inhibition of NOGO and NOGO receptor genes | |
US20030186909A1 (en) | Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors | |
US20030140362A1 (en) | In vivo models for screening inhibitors of hepatitis B virus | |
US20030134806A1 (en) | Method and reagent for the inhibition of grid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |